Ken Griffin Uro Gen Pharma Ltd. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,800 shares of URGN stock, worth $116,228. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,800

Previous 25,000 60.8%

Holding current value

$116,228

Previous $419,000 70.41%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.7 - $17.92 $2.13 Million - $3.01 Million	167,704 Added 225.52%	242,066 $3.07 Million
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $32,385 - $48,883	2,546 Added 3.55%	74,362 $1.25 Million
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $995,190 - $1.39 Million	-72,063 Reduced 50.09%	71,816 $1.08 Million
Q4 2023 Feb 14, 2024	BUY	$10.87 - $15.93 $1.49 Million - $2.18 Million	136,883 Added 1956.59%	143,879 $2.16 Million
Q3 2023 Nov 14, 2023	SELL	$8.84 - $22.64 $362,298 - $927,877	-40,984 Reduced 85.42%	6,996 $98,000
Q2 2023 Aug 14, 2023	SELL	$8.75 - $14.29 $255,465 - $417,210	-29,196 Reduced 37.83%	47,980 $496,000
Q1 2023 May 15, 2023	BUY	$7.99 - $11.02 $225,629 - $311,193	28,239 Added 57.7%	77,176 $713,000
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.96 $265,880 - $421,183	35,216 Added 256.66%	48,937 $434,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $98,928 - $129,114	13,721 New	13,721 $114,000
Q3 2021 Nov 15, 2021	SELL	$14.31 - $18.39 $161,001 - $206,905	-11,251 Reduced 16.41%	57,298 $964,000
Q2 2021 Aug 16, 2021	BUY	$15.2 - $20.94 $465,180 - $640,847	30,604 Added 80.65%	68,549 $1.05 Million
Q1 2021 May 17, 2021	BUY	$17.99 - $26.96 $29,125 - $43,648	1,619 Added 4.46%	37,945 $739,000
Q4 2020 Feb 16, 2021	BUY	$17.54 - $25.43 $199,377 - $289,062	11,367 Added 45.54%	36,326 $655,000
Q3 2020 Nov 16, 2020	BUY	$18.81 - $26.42 $74,600 - $104,781	3,966 Added 18.89%	24,959 $481,000
Q2 2020 Aug 14, 2020	SELL	$16.5 - $29.7 $780,202 - $1.4 Million	-47,285 Reduced 69.25%	20,993 $548,000
Q1 2020 May 15, 2020	SELL	$13.68 - $34.6 $73,940 - $187,013	-5,405 Reduced 7.34%	68,278 $1.22 Million
Q4 2019 Feb 14, 2020	SELL	$21.11 - $34.86 $446,012 - $736,522	-21,128 Reduced 22.28%	73,683 $2.46 Million
Q3 2019 Nov 14, 2019	SELL	$23.83 - $36.44 $166,667 - $254,861	-6,994 Reduced 6.87%	94,811 $2.26 Million
Q2 2019 Aug 14, 2019	SELL	$32.75 - $40.35 $2.22 Million - $2.74 Million	-67,844 Reduced 39.99%	101,805 $3.66 Million
Q1 2019 May 15, 2019	SELL	$35.47 - $54.55 $7.26 Million - $11.2 Million	-204,683 Reduced 54.68%	169,649 $0
Q4 2018 Feb 14, 2019	BUY	$38.35 - $50.39 $3,758 - $4,938	98 Added 0.03%	374,332 $16.1 Million
Q3 2018 Nov 13, 2018	BUY	$41.65 - $51.7 $2.22 Million - $2.75 Million	53,200 Added 16.57%	374,234 $0
Q2 2018 Aug 10, 2018	BUY	$48.35 - $65.33 $11.6 Million - $15.7 Million	239,676 Added 294.59%	321,034 $0
Q1 2018 May 11, 2018	BUY	$38.64 - $57.54 $3.14 Million - $4.68 Million	81,358 New	81,358 $4.04 Million

Others Institutions Holding URGN

# of Institutions

130

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $270M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account